Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

Bariatric surgery is currently the most ... treatment of diabetes and obesity is currently limited. The glucagon-like peptide-1 receptor agonists improve glycemia and induce a modest weight ...

WEIGHT-loss jabs are taking the world by storm, with a staggering half a million of us now using them. The injections have ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

They're known to aid in blood sugar control and, now, weight loss — however, according to a sweeping new study, the popular ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...